Elan Commits to J&J Despite Tysabri Ruling
DUBLIN (
) -- Irish drugmaker
Elan
is committed to close a transaction with
Johnson & Johnson
(JNJ) - Get Report
as quickly as possible following a judge's ruling it has breached an agreement with
Biogen Idec
(BIIB) - Get Report
for the marketing of multiple sclerosis drug Tysabri.
J&J reached an agreement in July to take an 18.4% ownership stake in Elan for $1 billion. The deal allows Elan to get financing from J&J to buy Biogen's Tysabri stake if Biogen was to be acquired.
Biogen, however, in late July claimed the Elan/J&J deal breached the Tysabri agreement. A federal judge agreed Thursday and the ruling means Elan must fix the J&J pact by the end of the month or it could risk losing all rights to Tysabri, a drug which is on track to generate about $1 billion in revenue this year.
" We respect the court's decision and the expedited attention in this matter," Elan said in a statement. "We are committed to working with Johnson & Johnson to close the transaction as quickly as possible, consistent with the Biogen-Elan Tysabri collaboration agreement."
-- Reported by Joseph Woelfel in New York
.
Follow TheStreet.com on
and become a fan on
